Retinitis Pigmentosa via the PRPH2 (RDS) Gene
Summary and Pricing
Test Method
Exome Sequencing with CNV DetectionTest Code | Test Copy Genes | Test CPT Code | Gene CPT Codes Copy CPT Code | Base Price | |
---|---|---|---|---|---|
9149 | PRPH2 | 81404 | 81404,81479 | $990 | Order Options and Pricing |
Pricing Comments
Our favored testing approach is exome based NextGen sequencing with CNV analysis. This will allow cost effective reflexing to PGxome or other exome based tests. However, if full gene Sanger sequencing is desired for STAT turnaround time, insurance, or other reasons, please see link below for Test Code, pricing, and turnaround time information. If the Sanger option is selected, CNV detection may be ordered through Test #600.
An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.
Click here for costs to reflex to whole PGxome (if original test is on PGxome Sequencing platform).
Click here for costs to reflex to whole PGnome (if original test is on PGnome Sequencing platform).
The Sanger Sequencing method for this test is NY State approved.
For Sanger Sequencing click here.Turnaround Time
3 weeks on average for standard orders or 2 weeks on average for STAT orders.
Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.
Targeted Testing
For ordering sequencing of targeted known variants, go to our Targeted Variants page.
Clinical Features and Genetics
Clinical Features
Genetics
Nonsyndromic and syndromic RP is remarkably heterogeneous both clinically and genetically. RP exhibits autosomal dominant (ad, 15%-25% of the cases), autosomal recessive (ar, 5%-20% of the cases) or X-linked (XL, 5%-15% of the cases) inheritance (Fahim et al. 2013). Unknown, simplex cases (single occurrence in a family) account for 40%-50%of cases, and digenic inheritance has been reported (Fahim et al. 2013). To date, over 60 genes have been linked to nonsyndromic (~56 genes) and syndromic RP (RetNet; Daiger et al. 2013). It has been reported that it is now possible to detect disease-causing variants in 56% of patients with adRP, roughly 30% of patients with recessive RP, and nearly 90% of patients with X-linked RP, which indicates that the there are several or many more RP genes that have yet to be discovered (Daiger et al. 2010).
The most common genes causing adRP are RHO (26-28% of all RP cases), PRPF31/RP11 (5-8%), PRPH2/RDS (4-8%), RP1 (6%), IMPDH1 (1-3%), KLHL7 (0.5-1.5%), NR2E3 (0.5-1.5%), PRPF3/RP18 (1%), PRPF8/RP13 (3%), CRX (1%) and TOPORS (1%) (Fahim et al. 2013; Daiger et al. 2010; Sullivan et al. 2013).
The PRPH2/RDS gene encodes a transmembrane glycoprotein expressed in vertebrate photoreceptors. It is localized to the rim of the disc membranes of the photoreceptor outer segments and helps in folding and stacking of the discs (Kohl et al. 1998). After the RHO gene, PRPH2 is one of the major causative genes for adRP (accounts for 4-8% of cases) (Fahim et al. 2013; Daiger et al. 2010; Sullivan et al. 2013). Over 90 different PRPH2 pathogenic variants (missense, nonsense, splicing, small and gross deletions, insertions and small indels) have been reported (Human Gene Mutation Database).
Clinical Sensitivity - Sequencing with CNV PGxome
After the RHO gene, PRPH2 is one of the major causative genes for adRP (accounts for 4-8% of cases) (Fahim et al. 2013; Daiger et al. 2010; Sullivan et al. 2013). A relatively high frequency of PRPH2 pathogenic variants (23%) was found in 61 unrelated autosomal dominant macular dystrophy (adMD) Spanish families (Gamundi et al. 2007).
Gross deletions or duplications in PRPH2 have only been rarely reported (Human Gene Mutation Database).
Testing Strategy
This test provides full coverage of all coding exons of the PRPH2 gene plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define full coverage as >20X NGS reads or Sanger sequencing. PGnome panels typically provide slightly increased coverage over the PGxome equivalent. PGnome sequencing panels have the added benefit of additional analysis and reporting of deep intronic regions (where applicable).
Dependent on the sequencing backbone selected for this testing, discounted reflex testing to any other similar backbone-based test is available (i.e., PGxome panel to whole PGxome; PGnome panel to whole PGnome).
Indications for Test
All patients with symptoms suggestive of autosomal dominant or sporadic RP. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in PRPH2.
All patients with symptoms suggestive of autosomal dominant or sporadic RP. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in PRPH2.
Citations
- Booij JC. et al. 2005. Journal of medical genetics. 42: e67. PubMed ID: 16272259
- Daiger SP. et al. 2010. Advances in experimental medicine and biology. 664: 325-31. PubMed ID: 20238032
- Daiger SP. et al. 2013. Clinical genetics. 84: 132-41. PubMed ID: 23701314
- Daiger SP. et al. 2013. Clinical genetics. 84: 132-41. PubMed ID: 23701314
- Fahim AT. et al. 2013. Retinitis Pigmentosa Overview. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong C-T, Smith RJ, and Stephens K, editors. GeneReviews(®), Seattle (WA): University of Washington, Seattle. PubMed ID: 20301590
- Fahim AT. et al. 2013. Retinitis Pigmentosa Overview. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong C-T, Smith RJ, and Stephens K, editors. GeneReviews(®), Seattle (WA): University of Washington, Seattle. PubMed ID: 20301590
- Gamundi MJ. et al. 2007. Molecular vision. 13: 1031-7. PubMed ID: 17653047
- Human Gene Mutation Database (Bio-base).
- Human Gene Mutation Database (Bio-base).
- Kohl S. et al. 1998. Acta anatomica. 162: 75-84. PubMed ID: 9831753
- RetNet: Genes and Mapped Loci Causing Retinal Diseases
- Sullivan LS. et al. 2013. Investigative ophthalmology & visual science. 54: 6255-61. PubMed ID: 23950152
- Sullivan LS. et al. 2013. Investigative ophthalmology & visual science. 54: 6255-61. PubMed ID: 23950152
- Van Soest S., Westerveld A. 1999. Survey of ophthalmology. 43: 321-34. PubMed ID: 10025514
Ordering/Specimens
Ordering Options
We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
- PGnome sequencing panels can be ordered via the myPrevent portal only at this time.
Requisition Form
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
For Requisition Forms, visit our Forms page
If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.
Specimen Types
Specimen Requirements and Shipping Details
PGxome (Exome) Sequencing Panel
PGnome (Genome) Sequencing Panel
ORDER OPTIONS
View Ordering Instructions1) Select Test Type
2) Select Additional Test Options
No Additional Test Options are available for this test.